AR and prostate cancer: The PI3K‐AKT‐mTOR signaling pathway is well known in prostate cancer for its critical role in tumor formation, cancer progression and drug resistance.[25] This potent prolonged inhibition of the AR response and mTOR signaling pathway by UBX‐390 explains its more potent anti‐proliferative and tumor growth inhibitory effects compared to ARV‐110.